Tenax CEO buys 10,850 shares around $1.85

TENAX THERAPEUTICS, INC.’s CEO bought 10,850 TENX common shares in mid-September 2026 and continues to hold several sizeable stock option awards.

Rhea-AI Filing Summary

TENAX THERAPEUTICS, INC. (TENX) reports that CEO and director Christopher Thomas Giordano purchased a total of 10,850 shares of common stock in two transactions on September 11 and September 15, 2026, at weighted average prices of about $1.88 and $1.82 per share. No Rule 10b5-1 trading plan is reported, and the filing also lists multiple existing stock option awards over several years with vesting schedules tied to continued employment.

Insider Trade Summary

Net Buyer: 10,850 shares

Net Buy 8 txns

Insider Giordano Christopher Thomas

Role CEO

Bought 10,850 shs ($20K)

Type	Security	Shares	Price	Value
Purchase	Common Stock F2	4,850	$1.8221	$9K
Purchase	Common Stock F1	6,000	$1.875	$11K
holding	Stock Option (right to buy) F3	--	--	--
holding	Stock Option (right to buy) F4	--	--	--
holding	Stock Option (right to buy) F5	--	--	--
holding	Stock Option (right to buy)	--	--	--
holding	Stock Option (right to buy) F6	--	--	--
holding	Stock Option (right to buy) F7	--	--	--

Holdings After Transaction: Common Stock — 22,174 shares (Direct); Stock Option (right to buy) — 3,092,000 contracts (Direct)

Footnotes (7)

1. F1. This transaction was executed in multiple trades at prices ranging from $1.87 to $1.88. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
2. F2. This transaction was executed in multiple trades at prices ranging from $1.82 to $1.83. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
3. F3. The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on January 9, 2027, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.
4. F4. The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on May 16, 2026, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.
5. F5. The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027, and May 17, 2028, subject to the Reporting Person's continued employment.
6. F6. The options vested and became exercisable as follows: 25% of the underlying shares of common stock vested and became exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026, subject to the Reporting Person's continued employment.
7. F7. The options vested and became exercisable as follows: 25% of the underlying shares of common stock vested and became exercisable on each of July 6, 2022, July 6, 2023, July 6, 2024, and July 6, 2025, subject to the Reporting Person's continued employment.

Key Figures

Common shares purchased September 11, 2026: 6,000 shares Weighted average purchase price September 11, 2026: $1.875 per share Common shares purchased September 15, 2026: 4,850 shares +4 more

7 metrics

Common shares purchased September 11, 2026 6,000 shares Direct purchase of TENAX THERAPEUTICS, INC. common stock by CEO

Weighted average purchase price September 11, 2026 $1.875 per share Trades executed between $1.87 and $1.88

Common shares purchased September 15, 2026 4,850 shares Direct purchase of TENAX THERAPEUTICS, INC. common stock by CEO

Weighted average purchase price September 15, 2026 $1.8221 per share Trades executed between $1.82 and $1.83

Option position expiring January 9, 2036 450,000 underlying shares at $13.30 Stock option on TENAX THERAPEUTICS, INC. common stock held directly

Option position expiring May 16, 2035 1,400,000 underlying shares at $5.89 Stock option on TENAX THERAPEUTICS, INC. common stock held directly

Option position expiring December 10, 2034 1,241,500 underlying shares at $5.94 Stock option on TENAX THERAPEUTICS, INC. common stock held directly

Key Terms

weighted average price, underlying shares of common stock, vest and become exercisable

3 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

underlying shares of common stock financial

"25% of the underlying shares of common stock vest and become exercisable"

vest and become exercisable financial

"The options vest and become exercisable as follows: 25% of the underlying shares"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did TENX CEO Christopher Giordano report in this Form 4?

He reported two purchases of TENAX THERAPEUTICS, INC. common stock, totaling 10,850 shares, on September 11, 2026 and September 15, 2026. Both were acquisitions of shares directly in his name, increasing his reported common stock position.

At what prices did the TENX CEO buy shares in September 2026?

On September 11, 2026, he bought 6,000 shares at a weighted average price of $1.875 per share, with individual trades between $1.87 and $1.88. On September 15, 2026, he bought 4,850 shares at a weighted average price of $1.8221, with trades between $1.82 and $1.83.

Were the September 2026 TENX insider purchases made under a Rule 10b5-1 plan?

No. The filing indicates that no Rule 10b5-1 trading plan applies to these transactions, meaning they are not identified as trades executed under a pre-arranged trading plan.

What stock option positions for the TENX CEO are disclosed in this Form 4?

The filing lists several stock option awards on TENAX THERAPEUTICS, INC. common stock, including options with exercise prices of $13.30 on 450,000 underlying shares expiring January 9, 2036, and $5.89 on 1,400,000 underlying shares expiring May 16, 2035, all held directly.

How do the TENX CEO’s stock options vest according to this disclosure?

For example, options on 450,000 underlying shares vest with 25% on January 9, 2027, then 1/36 of the remaining shares vest monthly over 36 months. Similar time-based vesting applies to other awards, all subject to continued employment.

Does the Form 4 state how many TENX shares the CEO owns after these purchases?

No specific total common share holding after the transactions is stated in this Form 4. The filing reports the 10,850 shares purchased and details multiple option positions, but does not print an updated aggregate common share balance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 09:39 PM Accepted by SEC EDGAR 09/15/2026 - 09:38 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Giordano Christopher Thomas

(Last) (First) (Middle)

101 GLEN LENNOX DRIVE, SUITE 300

(Street)

CHAPEL HILL NORTH CAROLINA 27517

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TENAX THERAPEUTICS, INC. [ TENX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2026		P		6,000	A	$1.875(1)	17,324	D
Common Stock	09/15/2026		P		4,850	A	$1.8221(2)	22,174	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$13.3							(3)	01/09/2036	Common Stock	450,000		450,000	D
Stock Option (right to buy)	$5.89							(4)	05/16/2035	Common Stock	1,400,000		1,400,000	D
Stock Option (right to buy)	$3.549							(5)	05/17/2034	Common Stock	218		218	D
Stock Option (right to buy)	$5.94							12/10/2025	12/10/2034	Common Stock	1,241,500		1,241,500	D
Stock Option (right to buy)	$992							(6)	06/09/2032	Common Stock	125		125	D
Stock Option (right to buy)	$3,152							(7)	07/06/2031	Common Stock	157		157	D

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $1.87 to $1.88. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

2. This transaction was executed in multiple trades at prices ranging from $1.82 to $1.83. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

3. The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on January 9, 2027, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.

4. The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on May 16, 2026, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.

5. The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027, and May 17, 2028, subject to the Reporting Person's continued employment.

6. The options vested and became exercisable as follows: 25% of the underlying shares of common stock vested and became exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026, subject to the Reporting Person's continued employment.

7. The options vested and became exercisable as follows: 25% of the underlying shares of common stock vested and became exercisable on each of July 6, 2022, July 6, 2023, July 6, 2024, and July 6, 2025, subject to the Reporting Person's continued employment.

	/s/ S. Halle Vakani, as Attorney-in-Fact	09/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)